Vanguard Group
KYNB

Vanguard Group’s Kyntra Bio KYNB Stock Holding History

Vanguard Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.6M Sell
181,973
-2,271
-1% -$22.2K ﹤0.01% 3631
2025
Q3 		$2.26M Buy
184,244
+6,204
+3% +$58.3K ﹤0.01% 3542
2025
Q2 		$944K Sell
178,040
-56,325
-24% -$411K ﹤0.01% 3758
2025
Q1 		$1.82M Sell
234,365
-714
-0.3% -$8.56K ﹤0.01% 3519
2024
Q4 		$3.11M Sell
235,079
-215
-0.1% -$2K ﹤0.01% 3436
2024
Q3 		$2.35M Sell
235,294
-115
-0% -$1.74K ﹤0.01% 3507
2024
Q2 		$5.25M Sell
235,409
-22,068
-9% -$682K ﹤0.01% 3237
2024
Q1 		$15.1M Sell
257,477
-24,289
-9% -$1.05M ﹤0.01% 2729
2023
Q4 		$6.24M Sell
281,766
-80,672
-22% -$1.22M ﹤0.01% 3196
2023
Q3 		$7.82M Sell
362,438
-27,160
-7% -$1.07M ﹤0.01% 3026
2023
Q2 		$26.3M Buy
389,598
+36,373
+10% +$15M ﹤0.01% 2475
2023
Q1 		$165M Sell
353,225
-24,538
-6% -$13M ﹤0.01% 1558
2022
Q4 		$151M Sell
377,763
-11,875
-3% -$4.55M ﹤0.01% 1588
2022
Q3 		$127M Buy
389,638
+2,763
+0.7% +$890K ﹤0.01% 1653
2022
Q2 		$102M Buy
386,875
+12,877
+3% +$3.29M ﹤0.01% 1815
2022
Q1 		$112M Buy
373,998
+12,550
+3% +$4.37M ﹤0.01% 1876
2021
Q4 		$127M Buy
361,448
+28,250
+8% +$8.8M ﹤0.01% 1850
2021
Q3 		$85.1M Buy
333,198
+17,444
+6% +$6.18M ﹤0.01% 2074
2021
Q2 		$210M Buy
315,754
+4,040
+1% +$2.33M 0.01% 1603
2021
Q1 		$270M Buy
311,714
+9,116
+3% +$9.71M 0.01% 1403
2020
Q4 		$281M Buy
302,598
+7,833
+3% +$8.23M 0.01% 1250
2020
Q3 		$303M Sell
294,765
-7,155
-2% -$7.7M 0.01% 1011
2020
Q2 		$306M Buy
301,920
+16,762
+6% +$15.6M 0.01% 1013
2020
Q1 		$248M Buy
285,158
+4,021
+1% +$4M 0.01% 1009
2019
Q4 		$301M Sell
281,137
-10,615
-4% -$10.8M 0.01% 1122
2019
Q3 		$270M Buy
291,752
+667
+0.2% +$733K 0.01% 1155
2019
Q2 		$329M Buy
291,085
+2,255
+0.8% +$2.47M 0.01% 1046
2019
Q1 		$392M Buy
288,830
+3,169
+1% +$4.3M 0.02% 911
2018
Q4 		$331M Buy
285,661
+8,786
+3% +$9.88M 0.01% 921
2018
Q3 		$421M Buy
276,875
+5,007
+2% +$7.71M 0.02% 887
2018
Q2 		$425M Buy
271,868
+12,417
+5% +$16.2M 0.02% 858
2018
Q1 		$300M Buy
259,451
+15,348
+6% +$20.2M 0.01% 1030
2017
Q4 		$289M Sell
244,103
-9,969
-4% -$12.5M 0.01% 1046
2017
Q3 		$342M Buy
254,072
+21,734
+9% +$22.9M 0.02% 930
2017
Q2 		$188M Buy
232,338
+30,457
+15% +$21.2M 0.01% 1268
2017
Q1 		$124M Buy
201,881
+15,711
+8% +$9.57M 0.01% 1534
2016
Q4 		$99.6M Buy
186,170
+5,656
+3% +$2.82M 0.01% 1615
2016
Q3 		$93.4M Buy
180,514
+11,706
+7% +$5.51M 0.01% 1603
2016
Q2 		$69.3M Buy
168,808
+13,589
+9% +$6.22M ﹤0.01% 1740
2016
Q1 		$82.6M Buy
155,219
+11,744
+8% +$5.85M 0.01% 1603
2015
Q4 		$109M Buy
143,475
+6,470
+5% +$4.29M 0.01% 1403
2015
Q3 		$75.1M Buy
137,005
+38,296
+39% +$23.2M 0.01% 1631
2015
Q2 		$58M Buy
98,709
+79,517
+414% +$46.2M ﹤0.01% 1854
2015
Q1 		$15.1M Buy
19,192
+18,593
+3,104% +$14.4M ﹤0.01% 2449
2014
Q4 		$409K Buy
+599
New +$385K ﹤0.01% 3787

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group's KYNB Position: Q4 2025 in Review

Vanguard Group reduced its Kyntra Bio (KYNB) stake by 1.2% in Q4 2025, selling an estimated $22.2K and leaving 181,973 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3631.

Vanguard Group first reported a position in KYNB in Q4 2014 and has held it in 45 quarters since. The position peaked at $425M in Q2 2018. 34 funds tracked by Wall St. Rank hold KYNB as of Q4 2025.

  • Vanguard Group held 181,973 shares of Kyntra Bio worth $1.6M as of Q4 2025.
  • Vanguard Group sold 2,271 Kyntra Bio shares in Q4 2025, an estimated $22.2K.
  • Kyntra Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3631 holding.
  • Vanguard Group first reported a position in Kyntra Bio in Q4 2014 and has held it in 45 quarters since.
  • Vanguard Group's Kyntra Bio position peaked at $425M in Q2 2018.
  • 34 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.